


AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A compound of the formula:




wherein  $R^1$  is a substituted or unsubstituted N-containing cycloalkyl,

$R^2$  is carboxy or protected carboxy,



$A^1$  is a substituted or unsubstituted lower alkylene, a substituted or unsubstituted lower alkanyl-ylidene or a substituted or unsubstituted lower alkenylene,

$A^2$  is lower alkylene,

$A^3$  is a substituted or unsubstituted lower alkylene,




is a group of the formula:



wherein is a substituted or unsubstituted N-containing heterocyclic group,

X is O, S or NH,

Y is NH,



wherein

R<sup>3</sup> is hydrogen or lower alkyl,

ℓ, m and n are each the same or a different integer of 0 or 1,

and or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) The compound of claim 1, wherein


R<sup>1</sup> is a substituted or unsubstituted 3 to 8 membered cycloalkyl containing 1 to 3 nitrogen atom(s),

R<sup>2</sup> is a carboxy or an esterified carboxy,

A<sup>1</sup> is a substituted or unsubstituted lower alkylene, a substituted or unsubstituted lower alkanyl-ylidene or a substituted or unsubstituted lower alkenylene,

A<sup>2</sup> is lower alkylene,


A<sup>3</sup> is a substituted or unsubstituted lower alkylene,



is a substituted or unsubstituted saturated 3 to 8 membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), a substituted or unsubstituted unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), or a substituted or unsubstituted saturated 3 to 8-membered heteromonocyclic group containing 1 to 5 carbon atom(s), 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s),

X is O, S, or NH,

Y is NH, and



wherein

R<sup>3</sup> is hydrogen or lower alkyl;


ℓ is an integer of 0 or 1,

m is an integer of 0 or 1, and

n is an integer of 0 or 1.

3. (Currently Amended) The compound of claim 2, wherein

R<sup>1</sup> is an unsubstituted piperidyl or a substituted piperidyl containing 1 or 2 oxo or [5-(lower) alkyl-2-oxo-1,3-dioxol-4-yl](lower)alkyl,



is piperidyl, morpholinyl, tetrahydroquinolyl or pyrrolidinyl,

A<sup>3</sup> is an unsubstituted lower alkylene or a substituted lower alkylene containing 1 to 3 suitable substituent(s) selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl; (C<sub>2</sub>-C<sub>6</sub>)alkenyl; (C<sub>2</sub>-C<sub>6</sub>)alkynyl; phenyl; phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl; phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl having 1 to 4 (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halo (C<sub>1</sub>-C<sub>6</sub>) alkyl or (C<sub>1</sub>-C<sub>6</sub>)alkylene dioxy; (C<sub>1</sub>-C<sub>6</sub>)alkyl having unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s); cyano; amino; protected amino; and phenyl(C<sub>1</sub>-C<sub>6</sub>)alkylcarbamoyl;

R<sup>2</sup>, R<sup>3</sup>, A<sup>1</sup>, A<sup>2</sup>, X, Y or Z are each as defined in claim 2,

$\ell$  is an integer of 0,


$m$  is an integer of 0, and

$n$  is an integer of 0.

4. (Currently Amended) The compound of claim 3,

wherein

$R^1$  is an unsubstituted piperidyl or a substituted piperidyl containing 1 or 2 oxo or [5-(lower)alkyl-2-oxo-1,3-dioxol-4-yl](lower)alkyl,



is piperidyl, morpholinyl, tetrahydroquinolyl or pyrrolydiny,

$A^3$  is an unsubstituted lower alkylene or a substituted lower alkylene containing 1 to 3 suitable substituent(s) selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl; (C<sub>2</sub>-C<sub>6</sub>)alkenyl; (C<sub>2</sub>-C<sub>6</sub>)alkynyl; phenyl; phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl; phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl having 1 to 4 (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl or (C<sub>1</sub>-C<sub>6</sub>)alkylene dioxy; (C<sub>1</sub>-C<sub>6</sub>)alkyl having unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s); cyano; amino; (C<sub>1</sub>-C<sub>6</sub>)alkanoylamino; aroylamino which may have 1 to 3 hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen or phenyl; cyclo(C<sub>3</sub>-C<sub>6</sub>)alkylcarbonylamino; (C<sub>1</sub>-C<sub>6</sub>)alkoxy(C<sub>1</sub>-C<sub>6</sub>)alkylcarbonylamino; (C<sub>2</sub>-C<sub>6</sub>)carbonylamino; (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonylamino; phenylsulfonylamino; and phenyl(C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl;

$R^2$ ,  $R^3$ ,  $A^1$ ,  $A^2$ , X, Y or Z are each as defined in claim 3,

$\ell$  is an integer of 0,

$m$  is an integer of 0, and


n is an integer of 0.

5. (Currently Amended) The compound of claim 4, wherein


R<sup>1</sup> is piperidyl,

A<sup>1</sup> is a lower alkylene or a lower alkanyl-ylidene,

A<sup>3</sup> is an unsubstituted lower alkylene or a substituted lower alkylene containing a lower alkyl, a lower alkynyl or a lower alkanoylamino,



is piperidyl,



and


R<sup>2</sup>, R<sup>3</sup>, A<sup>2</sup>, Y, ℓ, m, and n are each as defined in claim 4.

6. (Currently Amended) The compound of claim 5, wherein

R<sup>3</sup> is hydrogen,

A<sup>1</sup> is a lower alkylene,

A<sup>3</sup> is a lower alkylene having a lower alkanoylamino, and

R<sup>1</sup>, A<sup>2</sup>, , X, Y and Z are each as defined in claim 5.


7. (Original) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-2(S)-acetylamino- $\beta$ -alanine or its hydrochloride.

8. (Currently Amended) The compound of claim 5, wherein

$R^3$  is hydrogen,

$A^1$  is a lower alkylene,

$A^3$  is a lower alkylene having a lower alkynyl, and

$R^1, R^2, A^2,$  , X, Y, Z,  $\ell$ , m and n are each as defined in claim 5.

9. (Original) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-3(S)-ethynyl- $\beta$ -alanine.


10. (Currently Amended) The compound of claim 4, wherein

$R^1$  is piperidyl,

$A^1$  is a lower alkylene or a lower alkanylylidene,

$A^3$  is an unsubstituted lower alkylene or a substituted lower alkylene containing a lower alkyl, a lower alkynyl or a lower alkanoylamino,

 is morpholinyl,



and


$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{A}^2$ , Y,  $\ell$ , m and n are each as defined in claim 4.

11. (Currently Amended): A compound of claim 10 5, wherein

$\text{R}^1$  is piperidyl,

$\text{A}^1$  is a lower alkylene,


$\text{A}^3$  is a lower alkylene,



$\text{R}^3$  is hydrogen,


~~$\text{A}^1$  is lower alkylene,~~

~~$\text{A}^3$  is lower alkylene,~~ and



12. (Original) N-[4-{3-(4-piperidyl)propionyl)-2-morpholinylcarbonyl}-β-alanine or  
 its hydrochloride.

13. (Currently Amended) A process for preparing a compound of the formula:



wherein


$R^1$  is a substituted or unsubstituted N-containing cycloalkyl,


$R^2$  is a carboxy or a protected carboxy,


$A^1$  is a substituted or unsubstituted lower alkylene, a substituted or unsubstituted lower alkanyl-ylidene or a substituted or unsubstituted lower alkenylene,

$A^2$  is a lower alkylene,

$A^3$  is a substituted or unsubstituted lower alkylene,

 is a group of the formula:




wherein  is a substituted or unsubstituted N-containing heterocyclic group,

X is O, S or NH,

Y is NH,






(wherein  $\text{R}^3$  is hydrogen or lower alkyl), and


$\ell$ , m and n are each the same or a different integer of 0 or 1,

or a salt thereof, which comprises:

(i) reacting a compound of the formula





wherein  $\text{R}^1$ ,  $\text{A}^1$ , X and  $\ell$  are each as defined above, or its reactive derivative at the carboxy group or a salt thereof, with a compound of the formula:



wherein  $\text{R}^2$ ,  $\text{A}^2$ ,  $\text{A}^3$ ,  $\text{HN} \bigcirc$ , Z and n are each as defined above,


or its reactive derivative at the amino group or a salt thereof, to give a compound of the formula:





wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Z$ ,  $\ell$  and  $n$  are each as defined above,

or a salt thereof, or


(ii) reacting a compound of the formula:




wherein  $R^1$ ,  $A^1$ ,  $A^2$ , ,  $X$ ,  $\ell$  and  $n$  are each as defined above,  
or its reactive derivative at the carboxy group  
or a salt thereof, with a compound of the formula:




wherein R<sup>2</sup>, R<sup>3</sup> and A<sup>3</sup> are each as defined above, or its reactive derivative at the amino group or a salt thereof, to give a compound of the formula:





wherein  $R^1, R^2, R^3, A^1, A^2, A^3,$  ,  $X, \ell$  and  $n$  are each as defined above,

or a salt thereof, or

(iii) reacting a compound of the formula:





wherein  $R^1, A^1,$  ,  $X, Y, \ell$  and  $m$  are each as defined above, or its reactive derivative at the amino group or a salt thereof, with a compound of the formula




wherein  $R^2$  and  $A^3$  are each as defined above,


or its reactive derivative at the carboxy group or a salt thereof, to give a compound of the formula:





wherein  $R^1, R^2, A^1, A^3,$  ,  $X, Y, Q$  and  $m$  are each as defined above, or a salt thereof, or

(iv) subjecting a compound of the formula:





wherein  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $R_a^1$  is a substituted or unsubstituted N-containing cycloalkyl having amino protective group, or a salt thereof, to elimination reaction of the amino protective group, to give a compound of the formula:





wherein  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $R_b^1$  is a substituted or unsubstituted N-containing cycloalkyl, or a salt thereof, or

(v) subjecting a compound of the formula:





wherein  $R^1$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $R_a^2$  is protected carboxy, or a salt thereof, to elimination reaction of carboxy protective group, to give a compound of the formula:





wherein  $R^1$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, or a salt thereof, or

(vi) subjecting a compound of the formula:





wherein  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $R_b^1$  is a substituted or unsubstituted N-containing cycloalkyl, or a salt thereof, to protecting reaction of amino, to give a compound of the formula:





wherein  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $R_a^1$  is a substituted or unsubstituted N-containing cycloalkyl having amino protecting group, or a salt thereof, or

(vii) subjecting a compound of the formula:





wherein  $R^1$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, or its reactive derivative at the carboxy group or a salt thereof, to protecting reaction of the carboxy, to give a compound of the formula:





wherein  $R^1$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $R_a^2$  is a protected carboxy, or a salt thereof, or


(viii) subjecting a compound of the formula:





wherein  $R_b^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $A_a^3$  is lower alkylene having protected amino or a salt thereof, to elimination reaction of amino protective group, to give a compound of the formula:




wherein  $R^1_b$ ,  $R^2$ ,  $A^1$ ,  $A^2$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $A^3_b$  is a lower alkylene having an amino or a salt thereof, or  
 (ix) subjecting a compound of the formula:



wherein  $R^1_b$ ,  $R^2$ ,  $A^1$ ,  $A^2$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $A^3_b$  is lower alkylene having amino, or a salt thereof, to acylation reaction of amino, to give a compound of formula:



wherein  $R^1_b$ ,  $R^2$ ,  $A^1$ ,  $A^2$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are each as defined above, and  $A^3_c$  is lower alkylene having acylamino, or a salt thereof.


14. (Currently Amended) A pharmaceutical composition which comprises, as an active ingredient, at least one compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carriers or excipients.

15. (Canceled).

16. (Currently Amended) ~~The~~ A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, ~~wherein said compound or pharmaceutically acceptable salt thereof is admixed with~~ and a pharmaceutically suitable carrier.

17. (Previously Presented) A method for the treatment of diseases caused by thrombus formation; restenosis or reocclusion; the thrombus formation in case of vascular surgery, valve replacement, extracorporeal circulation or transplantation; disseminated intravascular coagulation; thrombotic thrombocytopenic; essential thrombocytosis; inflammation; or for the adjuvant therapy with thrombolytic drug or anticoagulant; which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

18. (Previously Presented) A compound of the formula:



wherein:

$R^1$  is a 6-membered cyclo(lower)alkyl containing 1 to 3 nitrogen atoms which may have one or more amino protective groups;

X is O, S or NH, and


$\ell$  is an integer of either 0 or 1;

$A^1$  is a substituted or unsubstituted lower alkylene, a substituted or unsubstituted lower alkenylene or a substituted or unsubstituted lower alkanyl-ylidene;



Y is NH, and



m is an integer of either 0 or 1;




is a group of the formula:



wherein is a substituted or unsubstituted 5 or 6-membered N-containing heterocyclic group containing 1 to 3 nitrogen atoms;

A<sup>2</sup> is a lower alkylene, and n is an integer of either 0 or 1;




wherein R<sup>3</sup> is hydrogen or a lower alkyl;

A<sup>3</sup> is a substituted or unsubstituted lower alkylene;

and R<sup>2</sup> is a carboxy or a protected carboxy;

or a pharmaceutically acceptable salt thereof.

19. (Previously Presented): A compound comprising the following structure:



wherein

$R^1$  is piperidyl, or piperidyl with one acyl;


X is O, S or NH, and

$\ell$  is an integer of 0;



$A^1$  is ethylene;

Y is NH, and

m is an integer of 0;




is a group of the formula:



$A^2$  is a lower alkylene, and

n is an integer of 0;



wherein  $R^3$  is hydrogen or a lower alkyl;

$A^3$  is ethylene, trimethylene or tetramethylene, each of which has one substituent selected from the group consisting of aryl, aryl(lower)alkyl and a heterocyclic group; and

and

$R^2$  is a carboxy or a protected carboxy;


or a pharmaceutically acceptable salt thereof.

20. (Previously Presented): The compound of Claim 19, wherein

$R^1$  is 4-piperidyl; and

$A^3$  is ethylene, trimethylene or tetramethylene, each of which has one substituent selected from the group consisting of phenyl, pyridyl, and quinolyl.

21. (Currently Amended) The compound of Claim 20, which is N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidyl-carbonyl]-3-phenyl-L-alanine or its acid addition salt of or a compound of the formula:



or its acid addition salt.

22. (Currently Amended) A method of producing a medicament, comprising mixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with at least one pharmaceutically suitable carrier or excipient.

23-24. (Cancelled)

25. (Previously Presented) The compound of claim 16, wherein said compound is N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine hydrochloride.


26. (Previously Presented) The method of claim 17, wherein said compound is N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine hydrochloride.


27. (Previously Presented) The method of claim 22, wherein said compound is N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine hydrochloride.

28. (Cancelled)


29. (Previously Presented) N-[(R)-1-{3-(4-piperidyl)propionyl}-3-piperidylcarbonyl]-β-alanine or its hydrochloride.


30. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13,  
 wherein said process comprises the process defined in section (i) of claim 13.


31. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13,  
 wherein said process comprises the process defined in section (ii) of claim 13.


32. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13,  
 wherein said process comprises the process defined in section (iii) of claim 13.


33. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13, wherein said process comprises the process defined in section (iv) of claim 13.


34. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13, wherein said process comprises the process defined in section (v) of claim 13.


35. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13,  
 wherein said process comprises the process defined in section (vi) of claim 13.


36. (Previously Presented) The process of claim 13 for preparing a compound of the formula:




wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13,  
 wherein said process comprises the process defined in section (vii) of claim 13.


37. (Previously Presented) The process of claim 13 for preparing a compound of the formula:



wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13,  
 wherein said process comprises the process defined in section (viii) of claim 13.

38. (Previously Presented) The process of claim 13 for preparing a compound of the formula:



wherein  $R^1$ ,  $R^2$ ,  $A^1$ ,  $A^2$ ,  $A^3$ , ,  $X$ ,  $Y$ ,  $Z$ ,  $\ell$ ,  $m$  and  $n$  are as defined in claim 13, wherein said process comprises the process defined in section (ix) of claim 13.

39. (Currently Amended) The A composition comprising the compound of Claim 1,  
~~wherein said compound is isolated.~~

40. (Currently Amended) The A composition comprising a reaction mixture  
containing the compound of Claim 1, wherein said compound is purified.

41. (Currently Amended) The A composition comprising the compound of Claim 1  
in combination with one or more pharmaceutically acceptable carriers or excipients, wherein  
~~said compound is chemically synthesized.~~

42. (Currently Amended) The compound of Claim 1, wherein  $R^1$  is selected from the group consisting of azetidiny, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, and quinolinyl.



43. (Currently Amended) The process of Claim 13, wherein R<sup>1</sup> is selected from the group consisting of azetidiny, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, and quinolinyl.

44. (Currently Amended) The compound of Claim 18, wherein R<sup>1</sup> is selected from the group consisting of azetidiny, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, and quinolinyl.

45. (Currently Amended) The A composition comprising the compound of Claim 18, ~~wherein said compound is isolated.~~

46. (Currently Amended) The A composition comprising a reaction mixture containing the compound of Claim 18, ~~wherein said compound is purified.~~

47. (Currently Amended) The A composition comprising an isolated or purified compound of Claim 18 in combination with one or more pharmaceutically acceptable carriers or excipients, ~~wherein said compound is chemically synthesized.~~